| Title: |
Circulating tumour DNA in patients with stage III colon cancer:multicentre prospective PROVENC3 study |
| Authors: |
Rubio-Alarcón, Carmen; Georgiadis,Andrew; Franken, Ingrid A; Wang,Haoyue; van Nassau, Sietske C M W; Schraa, Suzanna J; van der Kruijssen, Dave E W; van Rooijen, Karlijn; Linders,Theodora C; Delis-van Diemen,Pien; Alkemade,Maartje; Bolijn,Anne; Tijssen,Marianne; Lemmens,Margriet; Meiqari,Lana; Ketelaars,Steven L C; Closa-Mosquera,Adria; van Dongen,Miranda M W; Lanfermeijer,Mirthe; Lissenberg-Witte, Birgit I; Bosch,Linda J W; Bisschop-Snetselaar, Teunise; Adriaans, Bregje C; Greer,Amy; Riley,David; White,James R; Greco,Christopher; Cox,Liam; Fox,Jesse; Victor,Kaitlin; Leech,Catherine; Angiuoli,Samuel V; Kok,Niels F M; Punt,Cornelis J A; van den Broek,Daan; Koopman, Miriam; Meijer, Gerrit A; Velculescu,Victor E; Roodhart, Jeanine M L; Coupé,Veerle M H; Sausen,Mark; Vink, Geraldine R; Fijneman,Remond J A; Other Members of the PLCRC-MEDOCC Group; Onderzoek Medische Oncologie; Cancer; Unit Opleiding Aios; Externen Med. Onco; MS Medische Oncologie |
| Publication Year: |
2026 |
| Subject Terms: |
Aged; 80 and over; Biomarkers; Tumor/blood; Chemotherapy; Adjuvant; Circulating Tumor DNA/blood; Colonic Neoplasms/pathology; Female; Humans; Male; Middle Aged; Neoplasm Recurrence; Local; Neoplasm Staging; Neoplasm; Residual; Prognosis; Prospective Studies; Journal Article; Multicenter Study |
| Description: |
Background Circulating tumour DNA (ctDNA) is a promising biomarker to guide clinical decision-making. The aim of this study was to investigate the prognostic value of postoperative ctDNA in patients with stage III colon cancer who received adjuvant chemotherapy (ACT). Methods PROVENC3 was a multicentre prospective study of patients who underwent resection of pathological stage III colon cancer. Blood samples were collected at a median of 13 (interquartile range 4-20) days after resection. The presence of minimal residual disease was determined using Labcorp® Plasma Detect™, a novel tumour-informed whole genome sequencing (WGS) ctDNA test. The primary endpoint was 3-year time to recurrence (TTR). ctDNA status was further combined with pathological risk status to investigate the combined prognostic value. Results The median follow-up of the 209 patients who were included was 40 months. In total, 28 patients (13%) had detectable ctDNA after surgery. Postoperative ctDNA-positive patients had a worse TTR compared with ctDNA-negative patients (HR 6.2 (95% c.i. 3.4 to 11.2); P < 0.001). Of all ctDNA-positive patients, 36% did not develop recurrences during 3-year follow-up. Detectable ctDNA after ACT was associated with worse TTR (HR 7.9 (95% c.i. 3.9 to 15.9); P < 0.001). ctDNA status combined with pathological risk classification resulted in a 3-year recurrence risk that varied from 82% for pathological high-risk (pT4/N2) ctDNA-positive patients to 7% for pathological low-risk (pT1-3 N1) ctDNA-negative patients (HR 28.5 (95% c.i. 10.5 to 77.2); P < 0.001). Conclusion Postoperative ctDNA detection using a tumour-informed WGS test improves prognosis stratification in stage III colon cancer and may help to personalize adjuvant treatment. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
0007-1323 |
| Relation: |
https://dspace.library.uu.nl/handle/1874/469113 |
| Availability: |
https://dspace.library.uu.nl/handle/1874/469113 |
| Rights: |
info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.4AD1DC84 |
| Database: |
BASE |